AMRI: 선도적인 의약품 연구 및 개발 기관
1. Introduction
1.1. Company Background
Curia, formerly known as AMRI, is a contract research and manufacturing organization that provides services to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates globally, offering drug discovery, development, cGMP manufacturing, and aseptic fill and finish solutions.
1.2. Key Milestones
Over the years, Curia has achieved significant milestones in the pharmaceutical industry. The company has expanded its operations, acquired various entities, and made strategic investments to enhance its capabilities and offerings.
1.3. Locations and Facilities
Curia has locations in the United States, Europe, and Asia. The company’s facilities are equipped with state-of-the-art technologies and resources to support drug discovery, development, and manufacturing processes.
2. Services Offered
2.1. Drug Discovery
As a leading contract research organization, Curia offers comprehensive drug discovery services, including medicinal chemistry, biology, pharmacology, and more. The company’s expert team of scientists and researchers work collaboratively to identify and develop novel drug candidates.
2.2. Development
Curia provides drug development services to support clients in advancing their drug candidates towards clinical trials. With expertise in formulation development, analytical testing, and regulatory support, the company assists in accelerating the drug development process.
2.3. cGMP Manufacturing
Curia specializes in cGMP manufacturing of active pharmaceutical ingredients (APIs) and drug products. The company’s cGMP facilities adhere to strict quality standards and regulatory compliance to ensure the production of safe and effective pharmaceuticals.
3. Partnerships and Collaborations
3.1. Pfizer Inc.
Curia has established a strategic partnership with Pfizer Inc., a leading pharmaceutical company. Through this collaboration, Curia provides chemistry, research, development, and analytical services to support Pfizer’s drug discovery and development efforts.
3.2. Merck & Co.
Curia has a longstanding partnership with Merck & Co., a global healthcare company. The collaboration involves medicinal chemistry research, compound design, and synthesis activities aimed at advancing therapeutic solutions.
3.3. Takeda and AMRI
Curia has collaborated with Takeda, a pharmaceutical company, to work on various projects. The partnership focuses on specific research areas and aims to leverage the combined expertise of both companies to drive innovation and drug development initiatives.
4. Acquisition History
4.1. OsoBio Pharmaceuticals
AMRI acquired OsoBio Pharmaceuticals, a contract manufacturer specializing in aseptic filling, for $110 million in June 2014. This strategic acquisition enabled AMRI to enhance its capabilities in aseptic filling services and further expand its presence in the pharmaceutical manufacturing sector.
4.2. SSCI
In February 2015, AMRI acquired SSCI, a company based in West Lafayette, Indiana, that specializes in comprehensive cGMP solid-state chemistry research and analytical services for the pharmaceutical industry. This acquisition allowed AMRI to strengthen its offerings in solid-state analysis and further support drug development processes.
4.3. Gadea Pharmaceutical group
AMRI acquired Gadea Pharmaceutical group in July 2015 for $174 million. This acquisition expanded AMRI’s presence in the pharmaceutical manufacturing sector and provided access to new resources and expertise in drug development and manufacturing.
5. Research and Development Projects
5.1. National Cancer Institute Grant
In July 1997, AMRI received a $100,000 grant from the National Cancer Institute to design and synthesize compounds that inhibit a class of enzymes responsible for regulating the cell cycle. This research project exemplifies AMRI’s commitment to advancing drug discovery efforts in oncology.
5.2. Pfizer Collaboration Extension
AMRI extended its collaboration with Pfizer in 2001 for three additional years, providing chemistry, research, development, and analytical services. This partnership demonstrated AMRI’s capabilities in supporting pharmaceutical giants in their drug discovery and development endeavors.
5.3. National Institute of Drug Abuse Contract
In May 2004, AMRI was awarded a three-year contract by the National Institute of Drug Abuse to manufacture potential treatments for substance abuse. This contract underscored AMRI’s expertise in producing pharmaceutical products to address critical public health concerns.
6. Recent Developments
6.1. Name Change to Curia
In July 2021, AMRI underwent a significant rebranding and changed its name to Curia. This strategic decision reflects the company’s evolution and growth as a global leader in contract research and manufacturing services within the pharmaceutical and biotechnology industries.
6.2. Acquisition of Integrity Bio and LakePharma
In September 2021, Curia acquired Integrity Bio and LakePharma, biologics research, development, and manufacturing organizations, in undisclosed transactions. These acquisitions further diversified Curia’s service offerings and expanded its capabilities in biologics development and manufacturing.
6.3. Addition of Hua Tu as CTO
Following the acquisition of LakePharma, Hua Tu, co-founder and CEO of LakePharma, joined Curia’s executive team as the Chief Technology Officer. This addition brought valuable expertise and leadership to Curia’s biologics research and development operations.